We compared four primer sets from conserved regions of the hepatitis C virus (HCV) genome for their ability to detect HCV RNA in a "nested" cDNA polymerase chain reaction assay on sera from 114 anti-HCV antibodypositive individuals from around the world. The different primer sets had equivalent sensitivity, detecting <1 chimpanzee IDSO (dose that infects 50%) when tested against reference strain H of HCV. We tested equal amounts of RNA extracted from the serum of each individual with the four primer sets. The set derived from two highly conserved domains within the 5' noncoding (NC) region of the HCV genome, which also share significant similarity with Pestivirus 5' NC sequences, was the most effective at detecting HCV RNA. AU samples positive for HCV RNA with any other primer set were also positive with the primer set from the 5' NC region, and the latter was at least 3 times more likely to detect HCV infection than a primer set from within the nonstructural protein 3-like gene region (P < 0.001). We had no false positive results in >500 negative controls interspersed among the test samples. The 5' NC region primer set detected HCV-specific RNA, verified by highstringency Southern blot hybridization and DNA sequencing, in 100% of 15 acute and 33 chronic non-A, non-B hepatitis patients from the United States, Europe, and Asia, and 10 hepatocellular carcinoma patients from Africa and Asia that tested negative for the hepatitis B virus-encoded surface antigen. In conclusion, use of an appropriate primer set is crucial for detecting HCV RNA in the serum of infected individuals.
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Hepatitis C virus (HCV) is a positive-stranded RNA virus that appears to be the etiological agent of most posttransfusion non-A, non-B (NANB) hepatitis cases (1) (2) (3) . Amplification of HCV RNA sequences by reverse transcription and cDNA polymerase chain reaction (cDNA PCR) is the only practical method currently available to demonstrate viremia in patients with HCV infection (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, genetic heterogeneity among different HCV strains (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) results in false-negative results in cDNA PCR assays because of primer and template mismatch. Therefore, to develop a reliable PCR assay for the diagnosis of HCV infection, we designed primers from conserved regions of the HCV genome (15, (28) (29) (30) and tested their ability to detect HCV RNA in a nested cDNA PCR assay in serum from 114 anti-HCV antibodypositive individuals from around the world. The results emphasize the importance of primer selection for the detection of HCV RNA.
MATERIALS AND METHODS
We tested serum samples from 114 individuals from 12 countries (Denmark, Dominican Republic, Germany, Hong Kong, India, Italy, Peru, South Africa, Sweden, Taiwan, United States, and Zaire) who were anti-HCV antibodypositive by a first-generation anti-HCV test (2) . The German and South African samples were selected for high titers of anti-HCV from larger anti-HCV-positive groups.
There To reduce the risk of contamination in PCR analysis, a number of precautions were taken (31) . Solutions and aliquots were prepared in a laboratory that was never used for HCV research. Extraction of RNA and transfer of samples from first to second PCR reaction tubes were performed under sterile conditions with sterile reagents. These procedures as well as gel electrophoresis of the final PCR product were performed in separate, self-contained areas that had never been exposed to recombinant HCV DNA. All solutions were pipeted with positive displacement pipets or with disposable pipets or pipet tips containing an aerosol barrier. In addition, gloves were changed after each contact. A negative control was included for every test sample to monitor for contamination as a source of false-positive results.
All sera were stored at -800C after receipt in our laboratory. RNA was extracted by a modification of the hot phenol method (32 
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phases were pooled and extracted at room temperature with an equal volume of water-saturated phenol and chloroform (1:1) and then with chloroform alone. RNA was precipitated by the addition of 400 p.l of 7.5 M ammonium acetate and 2 volumes of isopropanol and incubation at -20TC for at least 16 hr. After centrifugation, the RNA pellets were washed once with 70%6 ethanol, dried at 37TC, and resuspended in 100 1.l of water containing 10 mM dithiothreitol and 200 units of human placental ribonuclease inhibitor (RNasin, Promega). This RNA solution was immediately divided into 10-pul aliquots and stored at -80TC. In other studies, the RNA pellets were resuspended in 10 p.l of the above solution, and the entire RNA sample was used for synthesis of cDNA.
Synthetic oligonucleotides, based on published HCV sequences (15, 33) , were synthesized on an Applied Biosystems model 391 DNA synthesizer. Primer sets a-d were designed from conserved regions of the HCV genome (Table 1 ). Prior to cDNA synthesis, a 10-pl aliquot of the RNA solution was thawed at room temperature, heated to 65TC for 2 min, chilled on ice, and used immediately. 940C for 1 min, primer annealing at 450C for 2 min, and amplification at 720C for 3 min. For the second round of PCR amplification, a 10-pl aliquot of the first PCR reaction was amplified as described above except for the substitution of internal sense and antisense primers. Finally, 10 p1 of the PCR product from the second round of amplification was analyzed by electrophoresis on a 2% agarose gel, staining with ethidium bromide, and visualization under ultraviolet light.
Specificity of selected DNA bands was confirmed by high-stringency Southern blot hybridization (SBH) and by partial sequence analysis. SBH of DNA bands amplified with primer set a was performed as described (35) except that the hybridization probe was a 5'-end-labeled oligonucleotide ( Statistical analysis was performed to determine the significance of the differences in the ability of the different primer sets to detect HCV RNA. The binomial and McNemar tests were used (37). (1992) RESULTS The purpose of this study was to compare different primer sets to determine whether a particular set was significantly better for detecting HCV RNA by PCR in sera from anti-HCV antibody-positive individuals from around the world. First, we analyzed the available HCV genomic sequences (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) 30) and found well-conserved domains in the virus 5' NC and protein-encoding gene regions. The 5' NC region, the most conserved region of the virus genome, possessed two domains that shared statistically significant similarity to Pestivirus 5' NC sequences (28, 30) . The structural and nonstructural regions were found to have various degrees of sequence heterogeneity, with the putative core and nonstructural protein number 3 (NS3)-like region being the most conserved. The protein-encoding gene regions did not possess statistically significant similarity to Pestivirus sequences. We selected four well-conserved regions of the HCV genome and designed four primer sets (i.e., a set is two pairs of nested primers) for comparison in a cDNA PCR assay (Table 1 ). Primer set a was from the two highly conserved domains within the 5' NC region of the HCV genome. Primer set b spanned the 5' end of the 5' NC region to the 5' end of the putative core gene sequence. Primer set c was derived from the 3' end of the 5' NC region to the 3' end of the core gene region, while primer set d was derived from within a conserved domain of the NS3-like gene of HCV. To assess the relative sensitivity of the four primer sets, we analyzed 10-fold serial dilutions of HCV RNA purified from HCV reference strain H (14, 30) , which has an infectivity titer of 106 5 CID50 doses/ml (a CID50 is the dose that infects 50%o of chimpanzees). We found that all four primer sets could detect HCV RNA at a dilution of 10-7 but not at 10-8 in our assay. Thus, the sensitivity of all primer sets was <1 CID50. Next, we tested the ability of the four primer sets to detect Pestivirus sequences. Only primer set a was capable of detecting bovine viral diarrhea virus RNA (strain NADL, American Type Culture Collection) in our cDNA PCR assay. This was an expected finding since primer set a was designed to correspond to the domain of the HCV 5' NC region that shared sequence similarity with animal Pestiviruses. To distinguish genuine HCV sequences from putative human Pestivirus sequences (38) that might be amplified by primer set a, we hybridized PCR products with an oligonucleotide probe specific for HCV but not Pestivirus sequences by SBH.
We tested sera from a total of 114 anti-HCV-positive individuals from 12 countries for the presence of HCV RNA using primer sets a-d in a cDNA PCR assay (Tables 2 and 3) . No false-positive results were found in >500 controls in the experiment. Primer set a was the most effective for detecting HCV RNA. A total of 84 (74%) of the 114 samples were positive with this primer set ( Table 2 ). The DNA bands from all 84 samples hybridized to our HCV-specific oligonucleotide probe under stringent conditions, thereby confirming the presence of genuine HCV RNA sequences in the test sera. Of the 84 positive samples, 80 were positive with at least one other primer set ( Table 3 ). The DNA bands from the four samples that had HCV RNA detectable only with primer set a were sequenced and each was found to represent a unique HCV sequence. Primer sets b and c were less effective at (24) detecting HCV RNA, with 68% and 52% of the sera testing positive, respectively. Primer set d was the least effective primer set tested and detected HCV RNA in only 24% of the sera. Differences could not be explained by loss of RNA, since under the storage conditions used, no degradation of RNA occurred during the course of the experiments (unpublished data). Thus, primer set a was at least 3 times more likely to detect HCV RNA than primer set d in our study. Analysis of the results obtained from patients with liver disease revealed the sensitivity of our PCR test, both in the standard assay (i.e., testing RNA extracted from the equivalent of 10 AI of serum) and in a more sensitive assay that used the most effective primer set (a) to detect HCV RNA extracted from 100 A.l of sera (Table 4 ). In our cDNA PCR assay using primer set a and RNA extracted from 10-100 Il of serum, we were able to detect HCV RNA in 100% of anti-HCV-positive patients with acute or chronic NANB hepatitis from the United States, Europe, and Asia, as well as HBsAg-negative HCC patients from Africa and Asia. Interestingly a patient with unspecified liver cirrhosis and another patient with biopsy-proven alcoholic liver cirrhosis were both HCV RNA-positive. In a third patient, with inactive liver cirrhosis, HCV RNA could not be detected. This initially anti-HCV-positive patient was later found to be negative with other commercially available anti-HCV assays and most likely had had autoimmune liver disease.
DISCUSSION
There are several important factors to consider when comparing primer sets in a cDNA PCR assay for their ability to detect HCV RNA in sera from different regions of the world. First, the genomic sequences used to design the primers must be well conserved to ensure optimal sensitivity. We designed our primer sets to correspond to regions of the HCV genome that are conserved in known HCV sequences. Second, it was necessary to demonstrate that all of the primer sets can detect an equivalent amount of HCV RNA under standard conditions. We used the well-characterized pool of HCV strain H (14, 30) to show that our four primer sets could detect HCV RNA at a level of <1 CID50. A third important factor was the elimination of false positive results caused by contamination of samples with exogenous HCV RNA. We paired each of the 114 sera with a negative control in the RNA extraction procedure and then performed each of the four PCR assays in parallel with a negative control. We did not have a single false-positive result in over 500 control samples tested. Also, SBH and DNA sequence analysis were used to verify that selected DNA bands, identified by agarose gel electrophoresis, represented unique HCV sequences. The final factor considered was that each of the four PCR reactions for a given serum sample should be performed on an equivalent amount of extracted RNA. With these conditions met, we believe that the results of the comparison accurately reflect the ability of the four primer sets to detect HCV RNA in sera collected worldwide.
Several groups have examined the effectiveness of different primer sets in detecting HCV RNA by PCR (4, 6, 13, 14, 34, (39) (40) (41) . The most comparable study, by Okamoto and coworkers (4), examined 10 sets of primers and found that those derived from the 5' NC and the putative core gene region were equivalent in their ability to detect HCV RNA in 10 anti-HCV-positive sera from Japanese individuals. Other studies have demonstrated enhanced detection of HCV RNA with primers from the 5' NC region compared with those specific for other regions (6, 39, 40) . Although these studies did not specifically address the factors discussed above, the results suggest that primers from the 5' end of the HCV genome are effective at detecting HCV RNA by PCR analysis.
Medical Sciences: Bukh et al. The goal of our investigation was to identify a primer set that had the lowest false-negative rate possible for the detection of HCV RNA worldwide in a cDNA PCR assay. Such a primer set would have to be specific for a conserved region of the virus genome. Therefore, we examined the 5' NC region, already known to be the most conserved region of the HCV genome, for domains that were completely conserved among available HCV sequences but also were conserved among available Pestivirus 5' NC sequences. Our rationale was that such sequences are likely to represent biologically important domains conserved in virus evolution and should be identical, or nearly identical, in all HCV genomes. The primer set derived from these conserved domains, primer set a, was the most effective set in detecting HCV RNA. HCV RNA was found in 84 (74%) of the sera tested from 114 anti-HCV-positive individuals. It was impressive that all samples that scored positive for HCV RNA with any of the other three primer sets also scored positive with primer set a. SBH and DNA sequence analysis demonstrated that all 84 samples possessed authentic HCV sequences. This indicates that putative human Pestivirus sequences were not present. Primer sets b and c, derived from different domains within both the 5' NC and the conserved core gene region (Tables 1 and 2 ) were able to detect HCV RNA in 92% and 70%, respectively, of the sera that were positive with primer set a. However, primer set d, derived from the NS3-like region, detected HCV RNA in only 32% of those sera positive for HCV RNA with primer set a. The difference between detection of HCV RNA using primer set a and the other three primer sets is statistically significant: with primer set b, the difference is significant at the P = 0.016 level, whereas with primer sets c and d, the difference is significant at the P < 0.001 level. Our results confirm the importance of using primer sets from the most conserved region of the HCV genome to avoid false-negative results caused by mismatch between primer and template resulting from the genetic heterogeneity (nucleotide substitutions, deletions, or insertions) among HCV strains.
Titration studies in chimpanzees have shown that the infectivity titer of HCV in patients with acute or chronic NANB hepatitis can be low, and the level of HCV RNA can be at or below the detection limit (<30 CID50/ml) of any cDNA PCR assay using 10 jl of serum. Therefore, a second aspect of this study was to perform PCR analysis with our most effective primer set on RNA extracted from 100 Al of selected sera. We found that there were five additional patient sera that possessed detectable HCV RNA: one chronic and four acute NANB hepatitis patients. However, there were also five anti-HCV-positive sera that did not contain detectable HCV RNA even after analysis of RNA from 100 ul of serum using primer set a (see Results). The lack of detection of virus RNA in these cases could result from: (i) a level of virus below the detection limit of our assay, (ii) the fact that the presence of anti-HCV was from a previous infection, (iii) nonspecificity of the antibody test (42, 43) , or (iv) loss of virus RNA due to poor handling of sera. We conclude that, for optimal detection of serum HCV RNA, primer set a should be used in a cDNA PCR assay on RNA extracted from 100 ,ul or more of serum.
Beyond the comparison of primer sets, we have made several noteworthy observations that have clinical significance. We found that 100% of patients with acute or chronic NANB hepatitis from the United States, Europe, and Asia, as well as HBsAg-negative HCC patients from Africa and Asia, were HCV RNA-positive in our cDNA PCR assay with primer set a. First, we were able to detect HCV RNA in all 33 chronic NANB hepatitis patients examined from Denmark (8 patients), Sweden (2 patients), Italy (12 patients), Hong Kong (5 patients), and Taiwan (6 patients). One other study (4) has reported a similar high frequency of detection of HCV RNA in a large number of patients from a single country (i.e., Japan). Taken together, these data clearly suggest that HCV Proc. Natl. Acad. Sci. USA 89 (1992) is the causative agent in all, or nearly all, of the cases of chronic NANB hepatitis in many parts of the world. Other studies (3, 5, 7, 22, 24, 41) of patients with chronic NANB hepatitis reported lower frequencies of the presence of HCV RNA. It is likely that there was a high rate of false negative results in the latter studies because primers were used that were derived from more heterogeneous regions of the HCV genome. Second, we detected HCV RNA in the serum of all 15 acute NANB hepatitis patients examined from Denmark (2 patients), Sweden (1 patient), and the United States (12 patients), suggesting that HCV is also the major causative agent in this group ofpatients in the countries studied. Similar data have been reported by others (8, 14) . Third, 14 of 17 HCC patients (13 from South Africa, 1 from Hong Kong, and 3 from Taiwan) were positive for HCV RNA in our PCR assay. In fact, all 10 HBsAg-negative patients (8 from South Africa and 2 from Taiwan) were HCV RNA-positive. These data confirm that HCV may play a major role in the development of HCC (7, 22) .
In the diagnosis of HCV infection by PCR, both sensitivity and specificity of the assay are of crucial importance (44, 45) . We find that careful attention to the selection of primer sets is essential for optimal detection of serum HCV RNA.
